We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Rare Kidney Cancer Marked by Molecular Features

By LabMedica International staff writers
Posted on 19 May 2020
Renal medullary carcinoma is a rare cancer of the kidney that predominantly afflicts young people of African descent who carry the sickle cell trait, sickle cell disease, or other sickle hemoglobinopathies that can cause sickling of the red blood cells.

Rare renal medullary carcinoma kidney cancers are marked by frequent focal chromosomal changes and other mutations that may inform future treatment strategies and renal medullary carcinoma (RMC) is a highly lethal malignancy. More...
Men are twice as likely to be affected by RMC as women, and about 70% of RMC cases start from the right kidney.

A large team of medical scientists from the University of Texas MD Anderson Cancer Center (Houston, TX, USA), and other centers in the USA and France used a combination of exome sequencing, RNA sequencing, fluorescence in situ hybridization (FISH), and multiplex ligation-dependent probe amplification (MLPA) analyses, and assessed 31 untreated renal medullary carcinoma tumors and 15 matched normal samples, identifying several recurrent copy number changes in the kidney cancers, from chromosome 8 gains and chromosome 22 losses to upregulated Notch signaling- and innate immune-related pathways.

In general, the team's results revealed recurrent copy number changes falling at focal chromosomal sites, and chromosome sites prone to structural changes in individuals with sickle cell blood traits. Such findings might help to explain why renal medullary carcinoma diagnoses are more frequent in individuals with the sickle cell trait, the authors noted. The kidney cancer is also over-represented in younger individuals with African ancestry.

In contrast to the low number of focal copy number alterations (CNAs) found in malignant rhabdoid tumors (MRT) and atypical teratoid/rhabdoid tumors (ATRT), the authors said they found that renal medullary carcinoma harbors a much more complex genome with high levels of focal CNAs. They also found that the tumors tended to have enhanced DNA replication stress related to SMARCB1 mutations. The replication stress not only contributed to the focal copy number changes, the investigators suggested, but also seemed to increase activity by the MYC signaling pathway, producing tumors predicted to be more apt to respond to DNA-damage repair-targeting drugs.

The authors concluded that they had identified the importance of SMARCB1 loss as a major recurrent genetic alteration in renal medullary carcinoma and found that it confers replication stress-induced vulnerabilities that can be therapeutically targeted. These results highlight a potential opportunity to utilize agents targeting replication stress pathways alone or in combination with other therapies to yield deep and durable therapeutic responses. The study was published on April 30, 2020 in the journal Cancer Cell.

Related Links:
University of Texas MD Anderson Cancer Center


New
Gold Member
Blood Gas Analyzer
Stat Profile pHOx
Serological Pipet Controller
PIPETBOY GENIUS
New
Modular Hemostasis Automation Solution
CN Track
New
Staining System
RAL DIFF-QUIK
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: A simple blood test could replace surgical biopsies for early detecion of heart transplant rejection (Photo courtesy of Shutterstock)

Blood Test Detects Organ Rejection in Heart Transplant Patients

Following a heart transplant, patients are required to undergo surgical biopsies so that physicians can assess the possibility of organ rejection. Rejection happens when the recipient’s immune system identifies... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.